When the Endogenous Hallucinogenic Trace Amine N,N-Dimethyltryptamine Meets the Sigma-1 Receptor Tsung-Ping Su, Teruo Hayashi

and D. Bruce Vaupel (10 March 2009) Science Signaling 2 (61), pe12. [DOI: 10.1126/scisignal.261pe12]

The following resources related to this article are available online at http://stke.sciencemag.org. This information is current as of 29 July 2010.

Article Tools Related Content

Visit the online version of this article to access the personalization and article tools: http://stke.sciencemag.org/cgi/content/full/sigtrans;2/61/pe12 The editors suggest related resources on Science's sites: http://stke.sciencemag.org/cgi/content/abstract/sigtrans;2/78/ec231 http://stke.sciencemag.org/cgi/content/abstract/sigtrans;2/73/ec180 http://stke.sciencemag.org/cgi/content/abstract/sigtrans;2/58/ec57 http://stke.sciencemag.org/cgi/content/abstract/sci;323/5916/934 http://stke.sciencemag.org/cgi/content/abstract/sigtrans;2007/411/tw400 http://stke.sciencemag.org/cgi/content/abstract/sigtrans;2000/60/pe1 This article has been cited by 1 article(s) hosted by HighWire Press; see: http://stke.sciencemag.org/cgi/content/full/sigtrans;2/61/pe12#BIBL This article cites 44 articles, 20 of which can be accessed for free: http://stke.sciencemag.org/cgi/content/full/sigtrans;2/61/pe12#otherarticles
Downloaded from stke.sciencemag.org on July 29, 2010

References

Glossary Permissions

Look up definitions for abbreviations and terms found in this article: http://stke.sciencemag.org/glossary/ Obtain information about reproducing this article: http://www.sciencemag.org/about/permissions.dtl

Science Signaling (ISSN 1937-9145) is published weekly, except the last week in December, by the American Association for the Advancement of Science, 1200 New York Avenue, NW, Washington, DC 20005. Copyright 2008 by the American Association for the Advancement of Science; all rights reserved.

26). norepinephrine. which reacted normally to the locomotor stimulating effect of methamphetamine. or the ability to suppress the magnitude of startle induced by an incoming acoustic signal that had been previously experienced (20). the locomotor-stimulating action of DMT resembles that of SKF10047 (24. Although DMT at 1 μM is as potent in eliciting cAMP accumulation as the prototypic trace amine tryptamine or LSD (19). and 5-hydroxytryptamine (5-HT). These results definitively link the action of DMT to the Sig-1R.N-Dimethyltryptamine Meets the Sigma-1 Receptor Tsung-Ping Su. however. it is unclear whether TAARs mediate the psychedelic effect of trace amines. tyramine. National Institute on Drug Abuse. e-mail. 333 Cassell Drive.1 D. *Corresponding author. high concentrations of DMT (100 μM.nih. 2010 www. However. specifically the 5-HT2A subtype. Downloaded from stke. about 7 times as high as its affinity for Sig-1R) could nonetheless inhibit voltage-gated sodium channels (24). including DMT. National Institute on Drug Abuse. Although this affinity is not impressive when compared to other Sig-1R ligands. a genetic study has demonstrated associations between polymor phisms in the TAAR4 subtype with susceptibility to schizophrenia (21). leading both groups to propose that DMT was an endogenous hallucinogen (4–6). Telephone. DMT is the main ingredient in the hallucinogenic beverage called “ayahuasca. as well as some of their metabolites or derivatives. Furthermore. Some amino acid metabolites are biogenic amines that. Saavedra and Axelrod then demonstrated the formation of DMT in rat and human brain (6). because TAAR antagonists have not been tested in humans in this regard.gov. did not become hyperactive in response to DMT (24). a phenomenon also observed with the prototypic Sig-1R agonist N-allylnormetazocine. Thus. do not involve the 5-HT system or other monoaminergic systems (16). 2Neuroimaging Research Branch. Furthermore. Department of Health and Human Services. and tryptamine. MD 21224.*1 Teruo Hayashi. an opiate analog better known as SKF-10047 (26). DMT is generally believed to exert its psychedelic effects through the 5-HT receptor. 1 Cellular humans (4. 5). Sig-1R knockout mice.sciencemag. TSU@intra.SCIENCESIGNALING. MD 21224. (19). 32).PERSPECTIVE NEUROSCIENCE When the Endogenous Hallucinogenic Trace Amine N. Here. it is possible that the psychedelic action of DMT might be mediated in part through sigma-1 receptors. TAs are purported to be involved in several human diseases (1). NIH Suite 3304. we focus on f indings related to N. 3). such as jerking.org on July 29. Several studies have since confirmed the psychedelic properties of DMT in humans (7–14).5 to 35 mg/kg administered intraperitoneally). DMT binds to the Sig1R with a moderate affinity at about 14 μM (24).org 10 March 2009 Vol 2 Issue 61 pe12 1 . These trace amines (TAs) include βphenylethylamine. including hallucination. which was identified by using the semisynthetic hallucinogen lysergic acid diethylamide (LSD) (15). USA. Intramural Research Program. we present a hypothetical signaling scheme that might be triggered by the binding of DMT to sigma-1 receptors. They are therefore a relevant animal model for schizophrenia because the PPI is typically impaired in schizophrenic patients (20). 333 Cassell Drive. which activate adenylyl cyclase and cause cyclic adenosine monophosphate (cAMP) accumulation (18. unlike the major neurotransmitter amines. However. synephrine. a hallmark action of Sig-1R ligands and Sig-1Rs (25). octopamine. and tremor. 333 Cassell Drive. the Sig-1R was recognized to be a nonopiate receptor (29–31) that might mediate the psychotomimetic effect not only of SKF10047 but also of the dissociative anesthetic phencyclidine (PCP) (28. a universal antagonist for all opiate receptor subtypes (28). Micromolar concentrations of DMT enhances phosphatidylinositol production in a manner that is not blocked by the 5-HT2A receptor antagonist ketanserin (17). Thus. 19). it was speculated that TAARs mediated part of the pharmacological or psychedelic effect of trace amines. conflicting reports later emerged that demonstrated a lack of association between the TAAR4 or TAAR6 gene and schizophrenia (22. Volume 2 Issue 61 pe12 N. Cellular Pathobiology Section. 23). With the discovery of the G protein–coupled TAassociated receptors (TAARs). including DMT. Baltimore. NIDA. DMT has been recently shown to bind sigma-1 receptors. fax. National Institutes of Health. Baltimore. Bruce Vaupel2 Published 10 March 2009. In addition. Here. A report now demonstrates that DMT targets a receptor called the sigma-1 receptor (Sig-1R) (24). Using purif ied DMT. USA. the same laboratory later found that the psychotomimetic effect of SKF-10047 was not reversed by naloxone. However. are typically present at low concentrations and accumulate in high amounts only if the amine-digestive enzyme monoamine oxidase is inhibited. The Sig-1R was originally thought to be the opiate receptor subtype that mediated the psychotomimetic or drug-induced psychotic-like effect of SKF-10047 in animals (27). certain behaviors seen in rats treated with DMT (0. such as (+)pentazocine (which has an affinity in nanomolar range).” which has been brewed (by boiling the bark of Banisteriopsis caapi together with the leaves of Psychotria viridis) and used by indigenous people around the South American Amazon basin (2. Cellular Neurobiology Research Branch. a tryptamine metabolite with psychedelic effects. it remains to be fully established whether TAARs mediate the psychotomimetic action of DMT.N-dimethyltryptamine (DMT) is a hallucinogen found endogenously in human brain that is commonly recognized to target the 5-hydroxytryptamine 2A receptor or the trace amine–associated receptor to exert its psychedelic effect. Thus. USA. 443-740-2804. 443-740-2142. TAAR1 knockout mice display a def icit in “prepulse inhibition” (PPI). gene association studies attempting to link TAARs and psychiatric disturbances have generated conflicting results as to whether TAARs are involved in schizophrenic symptomatologies. which are ligand-regulated molecular chaperones whose function includes inhibiting various voltage-sensitive ion channels. Department of Health and Human Services. retropulsion. Intramural Research Program. Baltimore. which suggests that part of the action of DMT is not mediated through 5-HT receptors. MD 21224. Szara and colleagues f irst reported the psychoactive effect of the compound in Pathobiology Section. such as dopamine.N-dimethyltryptamine (DMT). as well as LSD. IRP.nida. National Institutes of Health.

Sig-1R ligands might shift the site of action of Sig-1R chaperones from the center of the cell to its periphery. high concentrations of Sig-1R ligands may allow Sig-1Rs to directly interact with and inhibit channel proteins (24. why the channel-inhibiting concentration of DMT is almost 10 times as high as its affinity concentration (24). Sig-1Rs at the MAM enhance Ca2+ signaling from the ER into mitochondria (34.4. the acid-sensing ion channel (41). do sigma-1 receptors mediate the psychedelic effect of DMT? First.org 10 March 2009 Vol 2 Issue 61 pe12 2 . 1). High concentrations of Sig-1R ligands tonically inhibit the small conductance K+ (SK) channel. amnesia. We therefore speculate that Sig1Rs may partially mediate the psy- chotomimetic effects of DMT. Sig-1Rs and related molecules or organelles are illustrated in the postsynaptic region for the sake of simplicity. However. Sig-1Rs localize at the interface between the endoplasmic reticulum (ER) and mitochondrion.4 channel (38). 1. stroke. including (+)pentazocine and PRE-084. and P/Q-type Ca2+ channels (40). 35). 2010 BiP ER Ca2+ TCA Sig-1R BiP ATP production Mitochondria Low concentration of DMT High concentration of DMT Fig.5 channel (24. 38).SCIENCESIGNALING. such as visual hallucinations in humans (7–14). Secondly. the voltagegated N-. binding immunoglobulin protein (BiP). are not reported to cause psychotomimetic-like effects in animals (43). activates the tricarboxylic acid (TCA) cycle. they can translocate from the MAM to the plasma membrane (also termed the plasmalemma) or the subplasma membrane area when stimulated by higher concentrations (e. This may explain why higher concentrations of Sig1R ligands result in the inhibition of various ion channels at the plasma membrane and. PCP and SKF-10047 cause animals to behave as if they are hallucinating (they move their heads and eyes as if they are tracking objects in the air) (28). the KV1. at concentrations close to their Ki values. By stabilizing IP3 receptors. binding immunoglobulin protein (BiP) (34). and the volume-regulated Cl– channel (42) are also inhibited by high concentrations of Sig-1R ligands. particularly when ligands are present at concentrations close to their affinities (34).PERSPECTIVE PCP is thought to induce its mind-altering effect through the N-methyl. Sig-1R ligands. allowing them to act as molecular chaperones to inositol 1. at approximately 10-fold Ki) of Sig-1R ligands or when Sig-1Rs are overexpressed in cells (36–38) (Fig.D -aspartate (NMDA) receptor. (B) Higher concentrations of DMT cause the translocation of Sig-1Rs from the MAM to the plasma membrane. which is known as the mitochondria-associated ER membrane (MAM). Sig-1R agonists at affinity concentrations (i. Sig-1Rs have been implicated in diseases such as addiction. close to their Ki values) cause Sig-1Rs to disassociate from another ER chaperone. in particular. depression. 25). Thus.e. leading to the inhibition of ion channels.N-dimethyltryptamine through sigma-1 receptors.. although they may also be present presynaptically or in glia. moderate concentrations of selective Sig-1R ligands. This enhances Ca2+ signaling from the ER into mitochondria (34.g. allowing Sig-1Rs to chaperone inositol 1.org on July 29. we need to specify that Sig-1Rs have not been firmA DMT B Ion channel Inhibited ion channel Sig-1R Low DMT MAM sER High DMT IP3R Downloaded from stke. 35). which in turn leads to the potentiation of NMDA receptors (39). Although Sig-1Rs reside primarily at the ER. So. Hypothetical scheme illustrating the signaling of N. and cancer (33).4. pain. and increases adenosine triphosphate (ATP) production (35). By triggering the translocation of Sig1Rs from the MAM to the plasma membrane or subplasma membrane. The NaV1.5-trisphosphate (IP3) receptors. Could the psychotomimetic effect caused by PCP and SKF-10047 in animals (28) be explained by PCP or SKF-10047 blocking NMDA receptors and not by their binding to Sig-1Rs? www.. 1). In the present scheme. including DMT. L-. (A) Sigma-1 receptors (Sig-1Rs) at the mitochondrion-associated endoplasmic reticulum (ER) membrane (MAM) function as ligand-activated molecular chaperones. the possibility that Sig-1Rs are involved in psychotomimesis cannot be totally excluded at present. In addition to their postulated psychotomimetic action.5-trisphosphate receptors (IP3Rs) at the MAM (34). cause the dissociation of Sig-1Rs from another ER chaperone.sciencemag. ly established as being involved in causing psychotomimesis. thereby activating the tricarboxylic acid (TCA) cycle and increasing the production of adenosine triphosphate (ATP) (35) (Fig. and systematic behavioral studies are needed to differentiate between the SKF-10047– and PCP-induced effects mediated by the Sig-1R versus the NMDA receptor.

E. A. Neukirch. 373–389 (1976). Neuroendocrine. Kohn. Antonijoan. 98. 11. Harrison. 10. McKenna. C. Pharmacopsychiatry 38. P. Duan. L. the most important being: What is the physiological importance or relevance of the DMT signaling through Sig-1Rs? Furthermore. Gerald. which we know now is also a Sig-1R ligand. M. J. Obradovic. 9474–9475 (2001). Y. derailment. Strassman. Heekeren. M. R. J. Lichtblau. 63. 5. U. E. R. T. 14). B. Proc. R. The trace amine receptor 4 gene is not associated with schizophrenia in a sample linked to chromosome 6q23. R. Macciardi. Ethnopharmacol. Montero.N-dimethyltryptamine in humans. 73–83 (2003).A. A. Natl. Sanders. T. N. Waberski. C. lysergic acid diethylamide. Gouzoulis-Mayfrank. Towers. T. P. Qualls. Neukirch. K. heart. K. Gambelunghe. J. Neukirch. Biomed. Pu. S. 15. Proc. Natl. I. Pharmacol. C.N-dimethyltryptamine in rodents. Peroutka. E. Amphetamine. and pancreas (34). Acad. S. Callaway. B. Pathirana. Exp. Hung. 628–639 (2007). Hum. Nor do we know whether the chaperone-unleashing action seen at affinity concentrations of DMT or the ion channel–inhibiting action caused by high concentration of DMT relate to the psychedelic effect induced by DMT. E. Amann. E. 98–108 (1994). Morte. T. Urbano. K. K. C. K. S. 195–223 (1984). Kovar. and cardiovascular effects. Am. Saitou. A. Lancet. 9. although not designed to answer this question. L. 285–301 (1958). M. Kovar. J. Stoll.A. Dimethyltryptamine as a new psychotic agent. Identification of N. M. Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers. L. Stoll. R. J. 22. K. Mol. Psychopharmacol. The characterization of Sig-1Rs as ligand-regulated chaperone receptors (34) and the discovery of the endogenous hallucinogen DMT as a Sig-1R ligand (24) represent potential breakthroughs in drug abuse research. H. Kawohl.sciencemag. Pharmacol. Crowe. Thus. R. 624–638 (2004). For example. S. Hamdan. 37) (Fig. but also in peripheral organs such as the liver. Rossi. G. Pharmacol. 8966–8971 (2001). M. P. T. J. Arch. M. J. Pharmacol. M. 60. D. 37) to the plasma membrane to inhibit voltage-gated ion channels (24. DMT effects in humans might be mediated through Sig-1Rs or 5-HT2A receptors and not through blockade of NMDA receptors. Dimethyltryptamine: A new psychoactive drug. Kennedy. K. Kanyas. C. 11. W. R. M. Psychological effects of (S)-ketamine and N. Sci. Psychopharmacology (Berlin) 154. Pharmacol. II. Pierce. Sci. 6. A. R. Sai-Halasz. M. (Basel) 135. G. Branchek. Bacci. K. Deliganis. K. Durkin. DMT might first unleash the chaperone activity of the free form of Sig-1Rs at the MAM (34) and then cause the receptors to translocate (36.S. J. C. 10. S. Moller-Hartmann. Z. R. Neurol. G. 3. Qualls. Psychotomimetic Nmethylated tryptamines: formation in brain in vivo and in vitro. Uhlenhuth. Norra. J. Based on the current understanding of the cell biological actions of Sig-1Rs (34. Bonini. Thiel. M. Amara. Pharmacological modulation of the neural basis underlying inhibition of return (IOR) in the human 5HT2A agonist and NMDA antagonist model of psychosis. E. 21. Heekeren. Martinez. and at higher concentrations (100 μM) (24) might cause Sig-1Rs to translocate from the MAM to the plasma membrane (36. Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosis. Premont. Yritia. J. autonomic. L. Y. J. Neukirch. Strassman. Olson. A. Avidan. J. P. 306. N. Obradovic. monoamine metabolite secretion. Szara. Bennett Jr. Heekeren. A. the enzyme that synthesizes DMT from its precursor tryptamine (44) and Sig-1Rs (34) are particularly abundant in lung tissue. Thus. 8. D. Kitano. Science 175. Like other Sig-1R agonists (34). Bunzow. Barbanoj. P. E. D. 7. Subjective effects and preliminary results of a new rating scale. M. K. B. Quigley. R. Levinson. Gen. Downloaded from stke. and distractibility—than to the neurocognitive impairment seen with ketamine (11. A.SCIENCESIGNALING.N-dimethyltryptamine (DMT): A double blind. Ther. 2. Abbott. Moretti. 119–121 (2006). Swanson.N-dimethyltryptaime and beta-carbolines in psychotropic ayahuasca beverage. A. A. 21. I. 77–88 (2008). K. R. Gerald. 573–583 (2008). Riba. Beckmann. Adham. 1A). J. Saavedra. it will be important to delineate the roles of Sig-1Rs and their associated ligands. Dose-dependent study of N. E. Results from previously mentioned clinical studies. Hou. Kellner. 41. M. M. Biochem. D. Arttamangkul. Psychiatr. We do not know at present whether the chaperone activity of Sig-1Rs contributes to ion channel inhibition or whether Sig-1Rs associate with ion channels at the subplasma ER membrane or at the plasma membrane. Boyle. G. R. because it might be difficult to distinguish the psychedelic effect mediated by the NMDA receptor blockade from that mediated by Sig-1Rs in animal studies. C. Serotonin and lysergic acid diethylamide binding in rat brain membranes: Relationship to post-synaptic serotonin receptors. J. 18. Genet. 380P (1978).N-dimethyltryptamine (DMT) models of psychosis. Smith. to compare the psychedelic effect of DMT with that of ketamine. R. J. Caron. Arch. A. I. it would be interesting to examine whether Sig-1R antagonists block the psychedelic effect of DMT in humans. Zhong. F. 35. A. spleen. H. Sai-Halasz. The trace amine 1 receptor knockout mice: An animal model with relevance to schizophrenia. A. Branchek. Acad. Polymorphisms in the trace amine receptor 4 (TAAR4) gene on chromosome 6q23. 2010 www. 16. Daumann. 22. J. 6. 12. W. Barbanoj. Marsden. Thanki. which is also an NMDA receptor blocker like PCP (11–14). R. 98. J. K. Lakhlani. Wolinsky. Trace amines: Identification of a family of mammalian G proteincoupled receptors. 1365–1366 (1972). Daumann. D. including DMT. Gouzoulis-Mayfrank. F. R. Genes Brain Behav. J. 85–97 (1994). Gen. E. Morte. 17. Stock. Dose-response study of N. D. G. Ochoa. F. M. within the context of the physiology or pathophysiology of human diseases related to those organs. Mol. Gainetdinov. P. G. DMT at affinity concentrations (14 μM) (24) might cause the dissociation of Sig-1Rs from the Sig-1R-BiP complex (34. Acta Physiol. Daumann. Prepulse inhibition of the startle reflex and its attentional modulation in the human S-ketamine and N. L.2 are associated with susceptibility to schizophrenia. M. Gouzoulis-Mayfrank. A. V. J.N-dimethyltryptamine in humans. 38–42). By doing so. 38). Silverman. M. 301–311 (2005). X. 1). 1181–1188 (2001). 35) (Fig. More studies are needed to provide answers to these questions. Monoamine oxidase inhibitors in South American hallucinogenic plants: Tryptamine and beta-carboline constituents of ayahuasca. Jenner. Psychopharmacology (Berlin) 200.. Valle. Kouranova. M. has been used as a 5-HT2A agonist by Gouzoulis-Mayfrank et al. Mowry. Sig-1Rs are present not only in the central nervous system. A. Zhang. Behavioural changes induced by N. Magenis. P. 14. Lerer. DMT effects relate more to the paranoidtype psychoses with particular positive formal thought disorders—including loosening of associations. T. and pharmacokinetics. Boszormenyi. S. C. R. A. A. Almost 30 years after the initial description of a psychotomimesis-related sigma receptor (27–32). Gejman. D. Psychiatry 11. In this regard. Aroni. Artymyshyn. A clearer differentiation of the effects mediated by the two different receptors might come only from human studies. Differential interactions of dimethyltryptamine (DMT) with 5-HT1A and 5-HT2 receptors. Urbano. A. Br.org 10 March 2009 Vol 2 Issue 61 pe12 3 . J. References and Notes 1. Brunecker. Stock. Psychiatry 51. J. Pasumamula. V. H. cross-over study in healthy volunteers. S. T. Psychopharmacology (Berlin) 199. 1739–1744 (1991). S. A. Ogozalek. J. 13. Suchland. M.PERSPECTIVE It might not be. A. 19. Jones. Chromatogr. C. 78–79 (1957). C. N. Darland. Yet many questions remain. 75. J. lung. Heekeren. F. Raddatz. R.S. J. might provide some interesting clues. Grandy. 4. M. Rodrihuez-Fornells. B. C. C. P. investigators have identified DMT as an endogenous hallucinogen that targets a new site of action (24). we propose a hypothetical scheme for the molecular mechanism by which DMT signals through sigma-1 receptors (Fig. C. 1B). J. C. U. 3. K. A. Szara. Following the trace of elusive amines. J. B. adrenal gland. Mol. S. D. J. H. J. Riba. G. and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Sonders. Human pharmacology of ayahuasca: Subjective and cardiovascular effects.4methylenedioxymethamphetamine. Borowsky. Seeman. It is hoped that future research will increase our understanding of these roles. M. 12. Geyer. GouzoulisMayfrank.org on July 29. 1056–1059 (2008). DMT. Snyder. D. M. Borowsky. Axelrod. Psychiatry 51. T. Ben-Asher. 85–95 (2001). S. 20. H. 312–320 (2007).

R. 30. J. Pharmacol. D. The effects of morphineand nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. Kassiou. G. Y. 39. T. Naltrexone fails to antagonize the sigma effects of PCP and SKF-10047 in the dog. Renaudo. D. 41. X. Sci. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca2+ signaling and cell survival. Intracellular dynamics of sigma-1 receptors in NG-108-15 cells. 578. A. R. 32.sciencemag. Bruce. J. Imaging sigma receptors: Applications in drug development. T. Hayashi. J. J. A. 28. E. X. Hayashi. Guizouarn. 306. 8 (2007). Tovar. 223. Klyachko. 219–221 (1988). 44. Eades. Steroid binding at sigma receptors suggests a link between endocrine. Maurice. A. J. S. L. F. Pennypacker. B. 25. 36. Johannessen. 42. 249–254 (2009). 107.1126/scisignal. Vaupel. M. S. E. Gimenez. Martina. B. 24. A. 92. E. Hajipour. Des. Vaupel. Halman. Eur.-P. Begeron. P. Res. T. Ruoho. 491–502 (2008). 33. Fontanilla. Wu. Thompson. H. Neurophysiol. L. Pharmacol. N. O’Neill.-P. Generation and phenotypic analysis of sigma receptor type 1 (sigma 1) knockout mice. Su. 268. Dordal.org 10 March 2009 Vol 2 Issue 61 pe12 4 . Rizzuto. Department of Health and Human Services of the United States. 2259–2267 (2007). J. K. J. C. Cancer cell cycle modulated by a functional coupling between sigma-1 receptors and Cl. Jackson. Ther.-P. Montoliu. 143–157 (2007). Lan. F. Z. B.-P. Collier. Turcotte. Ther. Neurol. Monroy. A. G. 27. The trace amine associated receptor (TAAR6) gene is not associated with schizophrenia in the Irish case-control study of schizophrenia (ICCSS) sample. J. Wormley. 87. Waterhouse. J. P. Su. J. Hayashi. Exp. E. Ruoho. Lavado. 934–937 (2009). D. H. Exp. Huppler. P. Gilbert. The sigma-1 receptor modulates NMDA receptor synaptic transmission and plasticity via SK channels in rat hippocampus. Bowen. Willing. 596–610 (2007). Walsh. 239–247 (2002). and immune systems. L. Rodriguez. 2188–2196 (2003). Snyder. J. Langa. 35.261pe12 31. A.SCIENCESIGNALING. Feinstein. F. Downloaded from stke. D. Citation: T. R. Hellewell. O. 269–274 (1983). Herrera. Signal. 1. Largent. C. Aydar. Su. W. Neurosteroid dehydroepiandrosterone sulfate inhibits persistent sodium current in rat medial prefrontal cortex via activation of sigma-1 receptors. A. The sigma receptor as a ligand-regulated auxiliary potassium channel subunit. Science 240. P. B. Zamanillo. Su. V. Cheng. Curr. J. Cuevas. Y. Palmer. Hall. 34. K. Cozar. Biol. 2. D. Riley. T. When the endogenous hallucinogenic trace amine N.N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. Zhang. A. E. R. Zhu. W. Borgese. Mavlyutov. Enhanced antidepressant effect of sigma-1 receptor agonists in β25-35-amyloid peptide-treated mice. V. J. Pharm. Cozzi. Brain Res. Eur. 210. H. A. 327. Soriani. Exp. Roman. R. B. Y. Cantero. Cuevas. H. E. X. This work was supported by the Intramural Research Program of the National Institute on Drug Abuse. L. P. Science 134. Y. T. Neuron 34. Maher. 7–15 (1989). B. Katnik. Physiol. A. H. 29. Signal. 38. V. C. Condony. 517–532 (1976). Eur. 399–410 (2002). Enzymatic formation of psychotomimetic metabolites from normally occurring compounds. B. Neurosci. 284–290 (1982). 197. T. X. Ther. J. R. M. D. D. S. R. J. Cell 131. 282. T. J. Su. M. Pharmacol. Pharmacol. Hajnoczky.org on July 29. E. T. Hernandez. A. A. Mol.-P. Exp. Hayashi. Ma. B. Jackson. M. nervous. N. pe12 (2009). 134. I. 26. Sigma1 receptor modulation of acid-sensing ion channel a (ASICa) and ASICa-induced Ca2+ influx in rat cortical neurons. 2. T.N-dimethyltryptamine meets the sigma-1 receptor. 43. B. G. R. Zheng. W. Ther. M. Rat liver and kidney contain high densities of sigma-1 and sigma-2 receptors: Characterization by ligand binding and photoaffinity labeling. 2867–2879 (2002). S. www. J. M. 40. L’Hoste. D. P. Behav. 81 (2009). 10. Orringer. Neuropsychiatry Clin. Chem. Evidence for sigma opioid receptor: Binding of [3H]SKF-10047 to etorphine-inaccessible site in guinea pig brain. Schizophr. 19. M. Dong. A. A. F. Receptor mechanisms in antipsychotic drug action: Focus on sigma receptors. Jaffe. Martin. J. Exp. T. Neurosci. S. 18. Pharmacol. Romieu.channels. Perez. 726–733 (2003). Williams. 13. J. T. Trends Cell Biol. Urani. Sigma receptors inhibit high-voltage-activated calcium channels in rat sympathetic and parasympathetic neurons. London. E. Science 323. The hallucinogen N. 37. Su. Axelrod. 51–72 (2007). A. Pharmacol. Kendler. Vladimirov. 9–18 (1994). P. M. NIH.PERSPECTIVE 23. 128–136 (2008). J. T.-P. 343 (1961). D. V. Ligand-dependent localization and intracellular stability of sigma-1 receptors in CHO-K1 cells. 2010 45. Guitart. S.

Sign up to vote on this title
UsefulNot useful